Carlsmed’s (CARL) Buy Rating Reiterated at Truist Financial

Truist Financial reaffirmed their buy rating on shares of Carlsmed (NASDAQ:CARL) in a research report report published on Friday,Benzinga reports. They currently have a $20.00 price target on the stock, up from their prior price target of $18.00.

A number of other equities research analysts have also commented on CARL. Weiss Ratings initiated coverage on Carlsmed in a research report on Thursday, October 16th. They issued a “sell (e)” rating for the company. BTIG Research increased their target price on shares of Carlsmed from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $22.00.

Carlsmed Trading Up 14.9%

Shares of NASDAQ CARL opened at $13.66 on Friday. Carlsmed has a fifty-two week low of $11.76 and a fifty-two week high of $16.20. The company has a 50-day simple moving average of $13.59.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05. Carlsmed has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Carlsmed

Large investors have recently made changes to their positions in the business. Kornitzer Capital Management Inc. KS purchased a new position in shares of Carlsmed in the 3rd quarter worth about $736,000. Teacher Retirement System of Texas bought a new stake in Carlsmed in the third quarter worth about $2,343,000. TD Waterhouse Canada Inc. purchased a new position in Carlsmed in the third quarter valued at about $2,026,000. Board of Trustees of The Leland Stanford Junior University bought a new position in shares of Carlsmed during the 3rd quarter valued at approximately $335,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Carlsmed during the 3rd quarter worth approximately $3,042,000.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).